

Global Gastric Cancer Diagnostics Supply, Demand and Key Producers, 2023-2029

<https://marketpublishers.com/r/G0D8DB0AA9EEEN.html>

Date: April 2023

Pages: 115

Price: US\$ 4,480.00 (Single User License)

ID: G0D8DB0AA9EEEN

Abstracts

The global Gastric Cancer Diagnostics market size is expected to reach \$ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

This report studies the global Gastric Cancer Diagnostics demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Gastric Cancer Diagnostics, and provides market size (US\$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Gastric Cancer Diagnostics that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Gastric Cancer Diagnostics total market, 2018-2029, (USD Million)

Global Gastric Cancer Diagnostics total market by region & country, CAGR, 2018-2029, (USD Million)

U.S. VS China: Gastric Cancer Diagnostics total market, key domestic companies and share, (USD Million)

Global Gastric Cancer Diagnostics revenue by player and market share 2018-2023, (USD Million)

Global Gastric Cancer Diagnostics total market by Type, CAGR, 2018-2029, (USD

Million)

Global Gastric Cancer Diagnostics total market by Application, CAGR, 2018-2029, (USD Million)

This reports profiles major players in the global Gastric Cancer Diagnostics market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Myriad Genetics, ACON Laboratories, Teco Diagnostics, Vela Diagnostics, Abbott, AdvaCare Pharma, Fujirebio (An H.U. Group company), Thermo Fisher Scientific, F. Hoffmann-La Roche and General Electric, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Gastric Cancer Diagnostics market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US\$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Gastric Cancer Diagnostics Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Global Gastric Cancer Diagnostics Market, Segmentation by Type

Instrument

Reagent Consumables

Service

Global Gastric Cancer Diagnostics Market, Segmentation by Application

Male

Female

Companies Profiled:

Myriad Genetics

ACON Laboratories

Teco Diagnostics

Vela Diagnostics

Abbott, AdvaCare Pharma

Fujirebio (An H.U. Group company)

Thermo Fisher Scientific

F. Hoffmann-La Roche

General Electric

Agilent Technologies

Endofotonics

Biohit Oyj

BIOCEPT

FOUNDATION MEDICINE

DiaSorin S.p.A

Paragon Genomics

BIOM?RIEUX

QIAGEN

Key Questions Answered

1. How big is the global Gastric Cancer Diagnostics market?
2. What is the demand of the global Gastric Cancer Diagnostics market?
3. What is the year over year growth of the global Gastric Cancer Diagnostics market?
4. What is the total value of the global Gastric Cancer Diagnostics market?
5. Who are the major players in the global Gastric Cancer Diagnostics market?
6. What are the growth factors driving the market demand?

Contents

1 SUPPLY SUMMARY

- 1.1 Gastric Cancer Diagnostics Introduction
- 1.2 World Gastric Cancer Diagnostics Market Size & Forecast (2018 & 2022 & 2029)
- 1.3 World Gastric Cancer Diagnostics Total Market by Region (by Headquarter Location)
 - 1.3.1 World Gastric Cancer Diagnostics Market Size by Region (2018-2029), (by Headquarter Location)
 - 1.3.2 United States Gastric Cancer Diagnostics Market Size (2018-2029)
 - 1.3.3 China Gastric Cancer Diagnostics Market Size (2018-2029)
 - 1.3.4 Europe Gastric Cancer Diagnostics Market Size (2018-2029)
 - 1.3.5 Japan Gastric Cancer Diagnostics Market Size (2018-2029)
 - 1.3.6 South Korea Gastric Cancer Diagnostics Market Size (2018-2029)
 - 1.3.7 ASEAN Gastric Cancer Diagnostics Market Size (2018-2029)
 - 1.3.8 India Gastric Cancer Diagnostics Market Size (2018-2029)
- 1.4 Market Drivers, Restraints and Trends
 - 1.4.1 Gastric Cancer Diagnostics Market Drivers
 - 1.4.2 Factors Affecting Demand
 - 1.4.3 Gastric Cancer Diagnostics Major Market Trends
- 1.5 Influence of COVID-19 and Russia-Ukraine War
 - 1.5.1 Influence of COVID-19
 - 1.5.2 Influence of Russia-Ukraine War

2 DEMAND SUMMARY

- 2.1 World Gastric Cancer Diagnostics Consumption Value (2018-2029)
- 2.2 World Gastric Cancer Diagnostics Consumption Value by Region
 - 2.2.1 World Gastric Cancer Diagnostics Consumption Value by Region (2018-2023)
 - 2.2.2 World Gastric Cancer Diagnostics Consumption Value Forecast by Region (2024-2029)
- 2.3 United States Gastric Cancer Diagnostics Consumption Value (2018-2029)
- 2.4 China Gastric Cancer Diagnostics Consumption Value (2018-2029)
- 2.5 Europe Gastric Cancer Diagnostics Consumption Value (2018-2029)
- 2.6 Japan Gastric Cancer Diagnostics Consumption Value (2018-2029)
- 2.7 South Korea Gastric Cancer Diagnostics Consumption Value (2018-2029)
- 2.8 ASEAN Gastric Cancer Diagnostics Consumption Value (2018-2029)
- 2.9 India Gastric Cancer Diagnostics Consumption Value (2018-2029)

3 WORLD GASTRIC CANCER DIAGNOSTICS COMPANIES COMPETITIVE ANALYSIS

- 3.1 World Gastric Cancer Diagnostics Revenue by Player (2018-2023)
- 3.2 Industry Rank and Concentration Rate (CR)
 - 3.2.1 Global Gastric Cancer Diagnostics Industry Rank of Major Players
 - 3.2.2 Global Concentration Ratios (CR4) for Gastric Cancer Diagnostics in 2022
 - 3.2.3 Global Concentration Ratios (CR8) for Gastric Cancer Diagnostics in 2022
- 3.3 Gastric Cancer Diagnostics Company Evaluation Quadrant
- 3.4 Gastric Cancer Diagnostics Market: Overall Company Footprint Analysis
 - 3.4.1 Gastric Cancer Diagnostics Market: Region Footprint
 - 3.4.2 Gastric Cancer Diagnostics Market: Company Product Type Footprint
 - 3.4.3 Gastric Cancer Diagnostics Market: Company Product Application Footprint
- 3.5 Competitive Environment
 - 3.5.1 Historical Structure of the Industry
 - 3.5.2 Barriers of Market Entry
 - 3.5.3 Factors of Competition
- 3.6 Mergers, Acquisitions Activity

4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)

- 4.1 United States VS China: Gastric Cancer Diagnostics Revenue Comparison (by Headquarter Location)
 - 4.1.1 United States VS China: Gastric Cancer Diagnostics Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
 - 4.1.2 United States VS China: Gastric Cancer Diagnostics Revenue Market Share Comparison (2018 & 2022 & 2029)
- 4.2 United States Based Companies VS China Based Companies: Gastric Cancer Diagnostics Consumption Value Comparison
 - 4.2.1 United States VS China: Gastric Cancer Diagnostics Consumption Value Comparison (2018 & 2022 & 2029)
 - 4.2.2 United States VS China: Gastric Cancer Diagnostics Consumption Value Market Share Comparison (2018 & 2022 & 2029)
- 4.3 United States Based Gastric Cancer Diagnostics Companies and Market Share, 2018-2023
 - 4.3.1 United States Based Gastric Cancer Diagnostics Companies, Headquarters (States, Country)

- 4.3.2 United States Based Companies Gastric Cancer Diagnostics Revenue, (2018-2023)
- 4.4 China Based Companies Gastric Cancer Diagnostics Revenue and Market Share, 2018-2023
 - 4.4.1 China Based Gastric Cancer Diagnostics Companies, Company Headquarters (Province, Country)
 - 4.4.2 China Based Companies Gastric Cancer Diagnostics Revenue, (2018-2023)
- 4.5 Rest of World Based Gastric Cancer Diagnostics Companies and Market Share, 2018-2023
 - 4.5.1 Rest of World Based Gastric Cancer Diagnostics Companies, Headquarters (States, Country)
 - 4.5.2 Rest of World Based Companies Gastric Cancer Diagnostics Revenue, (2018-2023)

5 MARKET ANALYSIS BY TYPE

- 5.1 World Gastric Cancer Diagnostics Market Size Overview by Type: 2018 VS 2022 VS 2029
- 5.2 Segment Introduction by Type
 - 5.2.1 Instrument
 - 5.2.2 Reagent Consumables
 - 5.2.3 Service
- 5.3 Market Segment by Type
 - 5.3.1 World Gastric Cancer Diagnostics Market Size by Type (2018-2023)
 - 5.3.2 World Gastric Cancer Diagnostics Market Size by Type (2024-2029)
 - 5.3.3 World Gastric Cancer Diagnostics Market Size Market Share by Type (2018-2029)

6 MARKET ANALYSIS BY APPLICATION

- 6.1 World Gastric Cancer Diagnostics Market Size Overview by Application: 2018 VS 2022 VS 2029
- 6.2 Segment Introduction by Application
 - 6.2.1 Male
 - 6.2.2 Female
- 6.3 Market Segment by Application
 - 6.3.1 World Gastric Cancer Diagnostics Market Size by Application (2018-2023)
 - 6.3.2 World Gastric Cancer Diagnostics Market Size by Application (2024-2029)
 - 6.3.3 World Gastric Cancer Diagnostics Market Size by Application (2018-2029)

7 COMPANY PROFILES

7.1 Myriad Genetics

7.1.1 Myriad Genetics Details

7.1.2 Myriad Genetics Major Business

7.1.3 Myriad Genetics Gastric Cancer Diagnostics Product and Services

7.1.4 Myriad Genetics Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023)

7.1.5 Myriad Genetics Recent Developments/Updates

7.1.6 Myriad Genetics Competitive Strengths & Weaknesses

7.2 ACON Laboratories

7.2.1 ACON Laboratories Details

7.2.2 ACON Laboratories Major Business

7.2.3 ACON Laboratories Gastric Cancer Diagnostics Product and Services

7.2.4 ACON Laboratories Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023)

7.2.5 ACON Laboratories Recent Developments/Updates

7.2.6 ACON Laboratories Competitive Strengths & Weaknesses

7.3 Teco Diagnostics

7.3.1 Teco Diagnostics Details

7.3.2 Teco Diagnostics Major Business

7.3.3 Teco Diagnostics Gastric Cancer Diagnostics Product and Services

7.3.4 Teco Diagnostics Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023)

7.3.5 Teco Diagnostics Recent Developments/Updates

7.3.6 Teco Diagnostics Competitive Strengths & Weaknesses

7.4 Vela Diagnostics

7.4.1 Vela Diagnostics Details

7.4.2 Vela Diagnostics Major Business

7.4.3 Vela Diagnostics Gastric Cancer Diagnostics Product and Services

7.4.4 Vela Diagnostics Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023)

7.4.5 Vela Diagnostics Recent Developments/Updates

7.4.6 Vela Diagnostics Competitive Strengths & Weaknesses

7.5 Abbott, AdvaCare Pharma

7.5.1 Abbott, AdvaCare Pharma Details

7.5.2 Abbott, AdvaCare Pharma Major Business

7.5.3 Abbott, AdvaCare Pharma Gastric Cancer Diagnostics Product and Services

7.5.4 Abbott, AdvaCare Pharma Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023)

7.5.5 Abbott, AdvaCare Pharma Recent Developments/Updates

7.5.6 Abbott, AdvaCare Pharma Competitive Strengths & Weaknesses

7.6 Fujirebio (An H.U. Group company)

7.6.1 Fujirebio (An H.U. Group company) Details

7.6.2 Fujirebio (An H.U. Group company) Major Business

7.6.3 Fujirebio (An H.U. Group company) Gastric Cancer Diagnostics Product and Services

7.6.4 Fujirebio (An H.U. Group company) Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023)

7.6.5 Fujirebio (An H.U. Group company) Recent Developments/Updates

7.6.6 Fujirebio (An H.U. Group company) Competitive Strengths & Weaknesses

7.7 Thermo Fisher Scientific

7.7.1 Thermo Fisher Scientific Details

7.7.2 Thermo Fisher Scientific Major Business

7.7.3 Thermo Fisher Scientific Gastric Cancer Diagnostics Product and Services

7.7.4 Thermo Fisher Scientific Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023)

7.7.5 Thermo Fisher Scientific Recent Developments/Updates

7.7.6 Thermo Fisher Scientific Competitive Strengths & Weaknesses

7.8 F. Hoffmann-La Roche

7.8.1 F. Hoffmann-La Roche Details

7.8.2 F. Hoffmann-La Roche Major Business

7.8.3 F. Hoffmann-La Roche Gastric Cancer Diagnostics Product and Services

7.8.4 F. Hoffmann-La Roche Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023)

7.8.5 F. Hoffmann-La Roche Recent Developments/Updates

7.8.6 F. Hoffmann-La Roche Competitive Strengths & Weaknesses

7.9 General Electric

7.9.1 General Electric Details

7.9.2 General Electric Major Business

7.9.3 General Electric Gastric Cancer Diagnostics Product and Services

7.9.4 General Electric Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023)

7.9.5 General Electric Recent Developments/Updates

7.9.6 General Electric Competitive Strengths & Weaknesses

7.10 Agilent Technologies

7.10.1 Agilent Technologies Details

- 7.10.2 Agilent Technologies Major Business
- 7.10.3 Agilent Technologies Gastric Cancer Diagnostics Product and Services
- 7.10.4 Agilent Technologies Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
- 7.10.5 Agilent Technologies Recent Developments/Updates
- 7.10.6 Agilent Technologies Competitive Strengths & Weaknesses
- 7.11 Endofotonics
 - 7.11.1 Endofotonics Details
 - 7.11.2 Endofotonics Major Business
 - 7.11.3 Endofotonics Gastric Cancer Diagnostics Product and Services
 - 7.11.4 Endofotonics Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
 - 7.11.5 Endofotonics Recent Developments/Updates
 - 7.11.6 Endofotonics Competitive Strengths & Weaknesses
- 7.12 Biohit Oyj
 - 7.12.1 Biohit Oyj Details
 - 7.12.2 Biohit Oyj Major Business
 - 7.12.3 Biohit Oyj Gastric Cancer Diagnostics Product and Services
 - 7.12.4 Biohit Oyj Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
 - 7.12.5 Biohit Oyj Recent Developments/Updates
 - 7.12.6 Biohit Oyj Competitive Strengths & Weaknesses
- 7.13 BIOCEPT
 - 7.13.1 BIOCEPT Details
 - 7.13.2 BIOCEPT Major Business
 - 7.13.3 BIOCEPT Gastric Cancer Diagnostics Product and Services
 - 7.13.4 BIOCEPT Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
 - 7.13.5 BIOCEPT Recent Developments/Updates
 - 7.13.6 BIOCEPT Competitive Strengths & Weaknesses
- 7.14 FOUNDATION MEDICINE
 - 7.14.1 FOUNDATION MEDICINE Details
 - 7.14.2 FOUNDATION MEDICINE Major Business
 - 7.14.3 FOUNDATION MEDICINE Gastric Cancer Diagnostics Product and Services
 - 7.14.4 FOUNDATION MEDICINE Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
 - 7.14.5 FOUNDATION MEDICINE Recent Developments/Updates
 - 7.14.6 FOUNDATION MEDICINE Competitive Strengths & Weaknesses
- 7.15 DiaSorin S.p.A

- 7.15.1 DiaSorin S.p.A Details
- 7.15.2 DiaSorin S.p.A Major Business
- 7.15.3 DiaSorin S.p.A Gastric Cancer Diagnostics Product and Services
- 7.15.4 DiaSorin S.p.A Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
- 7.15.5 DiaSorin S.p.A Recent Developments/Updates
- 7.15.6 DiaSorin S.p.A Competitive Strengths & Weaknesses
- 7.16 Paragon Genomics
 - 7.16.1 Paragon Genomics Details
 - 7.16.2 Paragon Genomics Major Business
 - 7.16.3 Paragon Genomics Gastric Cancer Diagnostics Product and Services
 - 7.16.4 Paragon Genomics Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
 - 7.16.5 Paragon Genomics Recent Developments/Updates
 - 7.16.6 Paragon Genomics Competitive Strengths & Weaknesses
- 7.17 BIOM?RIEUX
 - 7.17.1 BIOM?RIEUX Details
 - 7.17.2 BIOM?RIEUX Major Business
 - 7.17.3 BIOM?RIEUX Gastric Cancer Diagnostics Product and Services
 - 7.17.4 BIOM?RIEUX Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
 - 7.17.5 BIOM?RIEUX Recent Developments/Updates
 - 7.17.6 BIOM?RIEUX Competitive Strengths & Weaknesses
- 7.18 QIAGEN
 - 7.18.1 QIAGEN Details
 - 7.18.2 QIAGEN Major Business
 - 7.18.3 QIAGEN Gastric Cancer Diagnostics Product and Services
 - 7.18.4 QIAGEN Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
 - 7.18.5 QIAGEN Recent Developments/Updates
 - 7.18.6 QIAGEN Competitive Strengths & Weaknesses

8 INDUSTRY CHAIN ANALYSIS

- 8.1 Gastric Cancer Diagnostics Industry Chain
- 8.2 Gastric Cancer Diagnostics Upstream Analysis
- 8.3 Gastric Cancer Diagnostics Midstream Analysis
- 8.4 Gastric Cancer Diagnostics Downstream Analysis

9 RESEARCH FINDINGS AND CONCLUSION

10 APPENDIX

10.1 Methodology

10.2 Research Process and Data Source

10.3 Disclaimer

List Of Tables

LIST OF TABLES

- Table 1. World Gastric Cancer Diagnostics Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
- Table 2. World Gastric Cancer Diagnostics Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
- Table 3. World Gastric Cancer Diagnostics Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
- Table 4. World Gastric Cancer Diagnostics Revenue Market Share by Region (2018-2023), (by Headquarter Location)
- Table 5. World Gastric Cancer Diagnostics Revenue Market Share by Region (2024-2029), (by Headquarter Location)
- Table 6. Major Market Trends
- Table 7. World Gastric Cancer Diagnostics Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
- Table 8. World Gastric Cancer Diagnostics Consumption Value by Region (2018-2023) & (USD Million)
- Table 9. World Gastric Cancer Diagnostics Consumption Value Forecast by Region (2024-2029) & (USD Million)
- Table 10. World Gastric Cancer Diagnostics Revenue by Player (2018-2023) & (USD Million)
- Table 11. Revenue Market Share of Key Gastric Cancer Diagnostics Players in 2022
- Table 12. World Gastric Cancer Diagnostics Industry Rank of Major Player, Based on Revenue in 2022
- Table 13. Global Gastric Cancer Diagnostics Company Evaluation Quadrant
- Table 14. Head Office of Key Gastric Cancer Diagnostics Player
- Table 15. Gastric Cancer Diagnostics Market: Company Product Type Footprint
- Table 16. Gastric Cancer Diagnostics Market: Company Product Application Footprint
- Table 17. Gastric Cancer Diagnostics Mergers & Acquisitions Activity
- Table 18. United States VS China Gastric Cancer Diagnostics Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
- Table 19. United States VS China Gastric Cancer Diagnostics Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
- Table 20. United States Based Gastric Cancer Diagnostics Companies, Headquarters (States, Country)
- Table 21. United States Based Companies Gastric Cancer Diagnostics Revenue, (2018-2023) & (USD Million)

Table 22. United States Based Companies Gastric Cancer Diagnostics Revenue Market Share (2018-2023)

Table 23. China Based Gastric Cancer Diagnostics Companies, Headquarters (Province, Country)

Table 24. China Based Companies Gastric Cancer Diagnostics Revenue, (2018-2023) & (USD Million)

Table 25. China Based Companies Gastric Cancer Diagnostics Revenue Market Share (2018-2023)

Table 26. Rest of World Based Gastric Cancer Diagnostics Companies, Headquarters (States, Country)

Table 27. Rest of World Based Companies Gastric Cancer Diagnostics Revenue, (2018-2023) & (USD Million)

Table 28. Rest of World Based Companies Gastric Cancer Diagnostics Revenue Market Share (2018-2023)

Table 29. World Gastric Cancer Diagnostics Market Size by Type, (USD Million), 2018 & 2022 & 2029

Table 30. World Gastric Cancer Diagnostics Market Size by Type (2018-2023) & (USD Million)

Table 31. World Gastric Cancer Diagnostics Market Size by Type (2024-2029) & (USD Million)

Table 32. World Gastric Cancer Diagnostics Market Size by Application, (USD Million), 2018 & 2022 & 2029

Table 33. World Gastric Cancer Diagnostics Market Size by Application (2018-2023) & (USD Million)

Table 34. World Gastric Cancer Diagnostics Market Size by Application (2024-2029) & (USD Million)

Table 35. Myriad Genetics Basic Information, Area Served and Competitors

Table 36. Myriad Genetics Major Business

Table 37. Myriad Genetics Gastric Cancer Diagnostics Product and Services

Table 38. Myriad Genetics Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 39. Myriad Genetics Recent Developments/Updates

Table 40. Myriad Genetics Competitive Strengths & Weaknesses

Table 41. ACON Laboratories Basic Information, Area Served and Competitors

Table 42. ACON Laboratories Major Business

Table 43. ACON Laboratories Gastric Cancer Diagnostics Product and Services

Table 44. ACON Laboratories Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 45. ACON Laboratories Recent Developments/Updates

- Table 46. ACON Laboratories Competitive Strengths & Weaknesses
- Table 47. Teco Diagnostics Basic Information, Area Served and Competitors
- Table 48. Teco Diagnostics Major Business
- Table 49. Teco Diagnostics Gastric Cancer Diagnostics Product and Services
- Table 50. Teco Diagnostics Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 51. Teco Diagnostics Recent Developments/Updates
- Table 52. Teco Diagnostics Competitive Strengths & Weaknesses
- Table 53. Vela Diagnostics Basic Information, Area Served and Competitors
- Table 54. Vela Diagnostics Major Business
- Table 55. Vela Diagnostics Gastric Cancer Diagnostics Product and Services
- Table 56. Vela Diagnostics Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 57. Vela Diagnostics Recent Developments/Updates
- Table 58. Vela Diagnostics Competitive Strengths & Weaknesses
- Table 59. Abbott, AdvaCare Pharma Basic Information, Area Served and Competitors
- Table 60. Abbott, AdvaCare Pharma Major Business
- Table 61. Abbott, AdvaCare Pharma Gastric Cancer Diagnostics Product and Services
- Table 62. Abbott, AdvaCare Pharma Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 63. Abbott, AdvaCare Pharma Recent Developments/Updates
- Table 64. Abbott, AdvaCare Pharma Competitive Strengths & Weaknesses
- Table 65. Fujirebio (An H.U. Group company) Basic Information, Area Served and Competitors
- Table 66. Fujirebio (An H.U. Group company) Major Business
- Table 67. Fujirebio (An H.U. Group company) Gastric Cancer Diagnostics Product and Services
- Table 68. Fujirebio (An H.U. Group company) Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 69. Fujirebio (An H.U. Group company) Recent Developments/Updates
- Table 70. Fujirebio (An H.U. Group company) Competitive Strengths & Weaknesses
- Table 71. Thermo Fisher Scientific Basic Information, Area Served and Competitors
- Table 72. Thermo Fisher Scientific Major Business
- Table 73. Thermo Fisher Scientific Gastric Cancer Diagnostics Product and Services
- Table 74. Thermo Fisher Scientific Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 75. Thermo Fisher Scientific Recent Developments/Updates
- Table 76. Thermo Fisher Scientific Competitive Strengths & Weaknesses
- Table 77. F. Hoffmann-La Roche Basic Information, Area Served and Competitors

- Table 78. F. Hoffmann-La Roche Major Business
- Table 79. F. Hoffmann-La Roche Gastric Cancer Diagnostics Product and Services
- Table 80. F. Hoffmann-La Roche Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 81. F. Hoffmann-La Roche Recent Developments/Updates
- Table 82. F. Hoffmann-La Roche Competitive Strengths & Weaknesses
- Table 83. General Electric Basic Information, Area Served and Competitors
- Table 84. General Electric Major Business
- Table 85. General Electric Gastric Cancer Diagnostics Product and Services
- Table 86. General Electric Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 87. General Electric Recent Developments/Updates
- Table 88. General Electric Competitive Strengths & Weaknesses
- Table 89. Agilent Technologies Basic Information, Area Served and Competitors
- Table 90. Agilent Technologies Major Business
- Table 91. Agilent Technologies Gastric Cancer Diagnostics Product and Services
- Table 92. Agilent Technologies Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 93. Agilent Technologies Recent Developments/Updates
- Table 94. Agilent Technologies Competitive Strengths & Weaknesses
- Table 95. Endofotonics Basic Information, Area Served and Competitors
- Table 96. Endofotonics Major Business
- Table 97. Endofotonics Gastric Cancer Diagnostics Product and Services
- Table 98. Endofotonics Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 99. Endofotonics Recent Developments/Updates
- Table 100. Endofotonics Competitive Strengths & Weaknesses
- Table 101. Biohit Oyj Basic Information, Area Served and Competitors
- Table 102. Biohit Oyj Major Business
- Table 103. Biohit Oyj Gastric Cancer Diagnostics Product and Services
- Table 104. Biohit Oyj Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 105. Biohit Oyj Recent Developments/Updates
- Table 106. Biohit Oyj Competitive Strengths & Weaknesses
- Table 107. BIOCEPT Basic Information, Area Served and Competitors
- Table 108. BIOCEPT Major Business
- Table 109. BIOCEPT Gastric Cancer Diagnostics Product and Services
- Table 110. BIOCEPT Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

- Table 111. BIOCEPT Recent Developments/Updates
- Table 112. BIOCEPT Competitive Strengths & Weaknesses
- Table 113. FOUNDATION MEDICINE Basic Information, Area Served and Competitors
- Table 114. FOUNDATION MEDICINE Major Business
- Table 115. FOUNDATION MEDICINE Gastric Cancer Diagnostics Product and Services
- Table 116. FOUNDATION MEDICINE Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 117. FOUNDATION MEDICINE Recent Developments/Updates
- Table 118. FOUNDATION MEDICINE Competitive Strengths & Weaknesses
- Table 119. DiaSorin S.p.A Basic Information, Area Served and Competitors
- Table 120. DiaSorin S.p.A Major Business
- Table 121. DiaSorin S.p.A Gastric Cancer Diagnostics Product and Services
- Table 122. DiaSorin S.p.A Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 123. DiaSorin S.p.A Recent Developments/Updates
- Table 124. DiaSorin S.p.A Competitive Strengths & Weaknesses
- Table 125. Paragon Genomics Basic Information, Area Served and Competitors
- Table 126. Paragon Genomics Major Business
- Table 127. Paragon Genomics Gastric Cancer Diagnostics Product and Services
- Table 128. Paragon Genomics Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 129. Paragon Genomics Recent Developments/Updates
- Table 130. Paragon Genomics Competitive Strengths & Weaknesses
- Table 131. BIOM?RIEUX Basic Information, Area Served and Competitors
- Table 132. BIOM?RIEUX Major Business
- Table 133. BIOM?RIEUX Gastric Cancer Diagnostics Product and Services
- Table 134. BIOM?RIEUX Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 135. BIOM?RIEUX Recent Developments/Updates
- Table 136. QIAGEN Basic Information, Area Served and Competitors
- Table 137. QIAGEN Major Business
- Table 138. QIAGEN Gastric Cancer Diagnostics Product and Services
- Table 139. QIAGEN Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 140. Global Key Players of Gastric Cancer Diagnostics Upstream (Raw Materials)
- Table 141. Gastric Cancer Diagnostics Typical Customers

List Of Figures

LIST OF FIGURES

Figure 1. Gastric Cancer Diagnostics Picture

Figure 2. World Gastric Cancer Diagnostics Total Market Size: 2018 & 2022 & 2029, (USD Million)

Figure 3. World Gastric Cancer Diagnostics Total Market Size (2018-2029) & (USD Million)

Figure 4. World Gastric Cancer Diagnostics Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)

Figure 5. World Gastric Cancer Diagnostics Revenue Market Share by Region (2018-2029), (by Headquarter Location)

Figure 6. United States Based Company Gastric Cancer Diagnostics Revenue (2018-2029) & (USD Million)

Figure 7. China Based Company Gastric Cancer Diagnostics Revenue (2018-2029) & (USD Million)

Figure 8. Europe Based Company Gastric Cancer Diagnostics Revenue (2018-2029) & (USD Million)

Figure 9. Japan Based Company Gastric Cancer Diagnostics Revenue (2018-2029) & (USD Million)

Figure 10. South Korea Based Company Gastric Cancer Diagnostics Revenue (2018-2029) & (USD Million)

Figure 11. ASEAN Based Company Gastric Cancer Diagnostics Revenue (2018-2029) & (USD Million)

Figure 12. India Based Company Gastric Cancer Diagnostics Revenue (2018-2029) & (USD Million)

Figure 13. Gastric Cancer Diagnostics Market Drivers

Figure 14. Factors Affecting Demand

Figure 15. World Gastric Cancer Diagnostics Consumption Value (2018-2029) & (USD Million)

Figure 16. World Gastric Cancer Diagnostics Consumption Value Market Share by Region (2018-2029)

Figure 17. United States Gastric Cancer Diagnostics Consumption Value (2018-2029) & (USD Million)

Figure 18. China Gastric Cancer Diagnostics Consumption Value (2018-2029) & (USD Million)

Figure 19. Europe Gastric Cancer Diagnostics Consumption Value (2018-2029) & (USD Million)

Figure 20. Japan Gastric Cancer Diagnostics Consumption Value (2018-2029) & (USD Million)

Figure 21. South Korea Gastric Cancer Diagnostics Consumption Value (2018-2029) & (USD Million)

Figure 22. ASEAN Gastric Cancer Diagnostics Consumption Value (2018-2029) & (USD Million)

Figure 23. India Gastric Cancer Diagnostics Consumption Value (2018-2029) & (USD Million)

Figure 24. Producer Shipments of Gastric Cancer Diagnostics by Player Revenue (\$MM) and Market Share (%): 2022

Figure 25. Global Four-firm Concentration Ratios (CR4) for Gastric Cancer Diagnostics Markets in 2022

Figure 26. Global Four-firm Concentration Ratios (CR8) for Gastric Cancer Diagnostics Markets in 2022

Figure 27. United States VS China: Gastric Cancer Diagnostics Revenue Market Share Comparison (2018 & 2022 & 2029)

Figure 28. United States VS China: Gastric Cancer Diagnostics Consumption Value Market Share Comparison (2018 & 2022 & 2029)

Figure 29. World Gastric Cancer Diagnostics Market Size by Type, (USD Million), 2018 & 2022 & 2029

Figure 30. World Gastric Cancer Diagnostics Market Size Market Share by Type in 2022

Figure 31. Instrument

Figure 32. Reagent Consumables

Figure 33. Service

Figure 34. World Gastric Cancer Diagnostics Market Size Market Share by Type (2018-2029)

Figure 35. World Gastric Cancer Diagnostics Market Size by Application, (USD Million), 2018 & 2022 & 2029

Figure 36. World Gastric Cancer Diagnostics Market Size Market Share by Application in 2022

Figure 37. Male

Figure 38. Female

Figure 39. Gastric Cancer Diagnostics Industrial Chain

Figure 40. Methodology

Figure 41. Research Process and Data Source

I would like to order

Product name: Global Gastric Cancer Diagnostics Supply, Demand and Key Producers, 2023-2029

Product link: <https://marketpublishers.com/r/G0D8DB0AA9EEEN.html>

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G0D8DB0AA9EEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970